Onkológia 4/2014

Nab-technologies, nab-paclitaxel and new treatment possibilities in the treatment of selected oncology diseases

Modern treatment of many oncology diseases has importantly prolonged the patients survival. Despite the progress in the treatment, there are some types of cancer where mortality remains unchanged. Nab-technology represents an innovative pharmacological modification of paclitaxel, which is still a standard product in the treatment of various oncology diseases. Binding the paclitaxel to nanoparticles of albumin resulted in the changes of pharmacological characteristics e. g., increased efficacy, decreased toxicity and important elimination of hypersensitive reactions. Treatment with nab-paclitaxel has been able to prolong survival in such a serious disease, like pancreatic adenocarcinoma.

Keywords: SPARC, paclitaxel, nanoparticular, gemcitabine, chemotherapy, pancreatic cancer, breast cancer.